{"title":"Newborn Screening for Spinal Muscular Atrophy: DNA Preparation from Dried Blood Spot and DNA Polymerase Selection in PCR.","authors":"Atsuko Takeuchi, Chisato Tode, Masayoshi Nishino, Yogik Onky Silvana Wijaya, Emma Tabe Eko Niba, Hiroyuki Awano, Yasuhiro Takeshima, Toshio Saito, Kayoko Saito, Poh San Lai, Yoshihiro Bouike, Hisahide Nishio, Masakazu Shinohara","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Polymerase chain reaction (PCR) analysis using DNA from dried blood spot (DBS) samples on filter paper is a critical technique for spinal muscular atrophy (SMA) newborn screening. However, DNA extraction from DBS is time-consuming, and elimination of PCR inhibitors from DBS is almost impossible.</p><p><strong>Methods: </strong>Exon 7 of the two homologous SMA-related genes, survival motor neuron (SMN) 1 and SMN2, of five SMA patients and five controls were amplified by PCR with a punched-out circle of the DBS paper. Two types of DNA preparation methods were tested; DNA-extraction (extracted DNA was added in a PCR tube) and non-DNA-extraction (a punched-out DBS circle was placed in a PCR tube). As for the DNA polymerases, two different enzymes were compared; TaKaRa Ex Taq™ and KOD FX Neo™. To test the diagnostic quality of PCR products, RFLP (Restriction fragment length polymorphism) analysis with DraI digestion was performed, differentiating SMN1 and SMN2.</p><p><strong>Results: </strong>In PCR using extracted DNA, sufficient amplification was achieved with TaKaRa Ex Taq™ and KOD FX Neo™, and there was no significant difference in amplification efficiency between them. In direct PCR with a punched-out DBS circle, sufficient amplification was achieved when KOD FX Neo™ polymerase was used, while there was no amplification with TaKaRa Ex Taq™. RFLP analysis of the direct PCR products with KOD FX Neo™ clearly separated SMN1 and SMN2 sequences and proved the presence of both of SMN1 and SMN2 in controls, and only SMN2 in SMA patients, suggesting that the direct PCR products with KOD FX Neo™ were of sufficient diagnostic quality for SMA testing.</p><p><strong>Conclusion: </strong>Direct PCR with DNA polymerases like KOD FX NeoTM has potential to be widely used in SMA newborn screening in the near future as it obviates the DNA extraction process from DBS and can precisely amplify the target sequences in spite of the presence of PCR inhibitors.</p>","PeriodicalId":39560,"journal":{"name":"Kobe Journal of Medical Sciences","volume":"65 3","pages":"E95-E99"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012323/pdf/kobej-65-e95.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kobe Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Polymerase chain reaction (PCR) analysis using DNA from dried blood spot (DBS) samples on filter paper is a critical technique for spinal muscular atrophy (SMA) newborn screening. However, DNA extraction from DBS is time-consuming, and elimination of PCR inhibitors from DBS is almost impossible.
Methods: Exon 7 of the two homologous SMA-related genes, survival motor neuron (SMN) 1 and SMN2, of five SMA patients and five controls were amplified by PCR with a punched-out circle of the DBS paper. Two types of DNA preparation methods were tested; DNA-extraction (extracted DNA was added in a PCR tube) and non-DNA-extraction (a punched-out DBS circle was placed in a PCR tube). As for the DNA polymerases, two different enzymes were compared; TaKaRa Ex Taq™ and KOD FX Neo™. To test the diagnostic quality of PCR products, RFLP (Restriction fragment length polymorphism) analysis with DraI digestion was performed, differentiating SMN1 and SMN2.
Results: In PCR using extracted DNA, sufficient amplification was achieved with TaKaRa Ex Taq™ and KOD FX Neo™, and there was no significant difference in amplification efficiency between them. In direct PCR with a punched-out DBS circle, sufficient amplification was achieved when KOD FX Neo™ polymerase was used, while there was no amplification with TaKaRa Ex Taq™. RFLP analysis of the direct PCR products with KOD FX Neo™ clearly separated SMN1 and SMN2 sequences and proved the presence of both of SMN1 and SMN2 in controls, and only SMN2 in SMA patients, suggesting that the direct PCR products with KOD FX Neo™ were of sufficient diagnostic quality for SMA testing.
Conclusion: Direct PCR with DNA polymerases like KOD FX NeoTM has potential to be widely used in SMA newborn screening in the near future as it obviates the DNA extraction process from DBS and can precisely amplify the target sequences in spite of the presence of PCR inhibitors.
背景:利用滤纸上的干血斑(DBS)样本DNA进行聚合酶链反应(PCR)分析是脊髓性肌萎缩症(SMA)新生儿筛查的一项关键技术。然而,从DBS中提取DNA非常耗时,而且从DBS中去除PCR抑制剂几乎是不可能的。方法:用DBS纸打孔圈PCR扩增5例SMA患者和5例对照的2个同源SMA相关基因SMN - 1和SMN2的外显子7。测试了两种DNA制备方法;DNA提取(将提取的DNA加入PCR管中)和非DNA提取(将打好的DBS环放入PCR管中)。在DNA聚合酶方面,比较了两种不同的酶;TaKaRa Ex Taq™和KOD FX Neo™。为检验PCR产物的诊断质量,采用DraI酶切法进行限制性内切片段长度多态性(RFLP)分析,区分SMN1和SMN2。结果:对提取的DNA进行PCR, TaKaRa Ex Taq™和KOD FX Neo™均能充分扩增,扩增效率无显著差异。在直接PCR中,使用KOD FX Neo™聚合酶可以获得充分的扩增,而使用TaKaRa Ex Taq™则没有扩增。KOD FX Neo™直接PCR产物的RFLP分析清楚地分离了SMN1和SMN2序列,并证明对照组中同时存在SMN1和SMN2,而SMA患者中仅存在SMN2,这表明KOD FX Neo™直接PCR产物具有足够的SMA诊断质量。结论:采用KOD FX NeoTM等DNA聚合酶进行直接PCR,避免了DBS DNA的提取过程,且在存在PCR抑制剂的情况下仍能精确扩增目标序列,具有在不久的将来广泛应用于SMA新生儿筛查的潜力。